Aclaris Therapeutics receives FDA approval for Eskata topical solution, 40%
Aclaris Therapeutics announced that the FDA has approved Eskata topical solution, 40% for the treatment of raised seborrheic keratoses, or SKs. SKs are non-cancerous skin growths that affect more than 83 million American adults and can be an aesthetic skin concern. SKs tend to increase in size and number with age. The condition is more prevalent than acne, psoriasis and rosacea combined. The FDA approval of Eskata is based on two pivotal Phase 3 trials that demonstrated the safety and efficacy of Eskata for the treatment of raised SKs. In these trials, patients received up to two treatments with Eskata, with one at treatment initiation and a second at week three. Patients treated with Eskata were more likely to have all four treated SKs completely cleared after two treatments than patients who received placebo. Treatment with Eskata was generally well tolerated, with the most common side effects being itching, stinging, crusting, swelling, redness and scaling at the site of application.